Revance Therapeutics, Inc. (NASDAQ:RVNC) Receives Average Recommendation of “Hold” from Analysts

0
176
Revance Therapeutics, Inc. (NASDAQ:RVNC) Receives Average Recommendation of “Hold” from Analysts



Revance Therapeutics, Inc. (NASDAQ:RVNC – Get Rating) has been given a consensus rating of “Hold” by the seven brokerages that are presently covering the company, MarketBeat reports. Two analysts have rated the stock with a sell recommendation, one has assigned a hold recommendation and four have given a buy recommendation to the company. The average 1-year price objective among analysts that have issued a report on the stock in the last year is $23.60.

Several research firms have issued reports on RVNC. StockNews.com began coverage on shares of Revance Therapeutics in a research note on Thursday, March 31st. They set a “sell” rating for the company. HC Wainwright restated a “buy” rating and issued a $18.00 target price on shares of Revance Therapeutics in a research note on Wednesday, January 19th. Finally, Zacks Investment Research downgraded shares of Revance Therapeutics from a “hold” rating to a “sell” rating in a research note on Friday, March 4th.

Several institutional investors and hedge funds have recently made changes to their positions in the business. Principal Financial Group Inc. lifted its position in shares of Revance Therapeutics by 7.6% in the first quarter. Principal Financial Group Inc. now owns 12,850 shares of the biopharmaceutical company’s stock worth $251,000 after purchasing an additional 913 shares in the last quarter. Teacher Retirement System of Texas grew its stake in shares of Revance Therapeutics by 7.6% in the first quarter. Teacher Retirement System of Texas now owns 13,921 shares of the biopharmaceutical company’s stock worth $271,000 after acquiring an additional 981 shares during the last quarter. Advisor Group Holdings Inc. grew its stake in shares of Revance Therapeutics by 60.6% in the first quarter. Advisor Group Holdings Inc. now owns 2,838 shares of the biopharmaceutical company’s stock worth $56,000 after acquiring an additional 1,071 shares during the last quarter. ProShare Advisors LLC grew its stake in shares of Revance Therapeutics by 4.5% in the fourth quarter. ProShare Advisors LLC now owns 25,425 shares of the biopharmaceutical company’s stock worth $414,000 after acquiring an additional 1,085 shares during the last quarter. Finally, Dark Forest Capital Management LP acquired a new stake in Revance Therapeutics during the third quarter worth $37,000. Institutional investors own 79.94% of the company’s stock.

Shares of RVNC stock opened at $13.15 on Friday. Revance Therapeutics has a one year low of $11.65 and a one year high of $33.83. The company has a debt-to-equity ratio of 4.10, a quick ratio of 3.51 and a current ratio of 3.66. The company has a 50 day moving average price of $17.68 and a 200 day moving average price of $15.61. The firm has a market capitalization of $939.32 million, a price-to-earnings ratio of -3.15 and a beta of 1.05.

Revance Therapeutics (NASDAQ:RVNC – Get Rating) last issued its quarterly earnings results on Monday, February 28th. The biopharmaceutical company reported ($0.93) EPS for the quarter, topping the consensus estimate of ($0.98) by $0.05. Revance Therapeutics had a negative net margin of 361.59% and a negative return on equity of 181.75%. The firm had revenue of $25.95 million during the quarter, compared to analyst estimates of $24.56 million. During the same quarter in the prior year, the business posted ($1.24) earnings per share. As a group, equities analysts forecast that Revance Therapeutics will post -3.56 EPS for the current fiscal year.

Revance Therapeutics Company Profile (Get Rating)

Revance Therapeutics, Inc, a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company’s lead drug candidate is DaxibotulinumtoxinA for injection, which has completed phase III clinical trials for the treatment of glabellar (frown) lines and cervical dystonia; is in phase II clinical trials to treat upper facial lines, moderate or severe dynamic forehead lines, and moderate or severe lateral canthal lines; and has completed Phase II clinical trials for the treatment of adult upper limb spasticity and plantar fasciitis.

See Also

Analyst Recommendations for Revance Therapeutics (NASDAQ:RVNC)



Receive News & Ratings for Revance Therapeutics Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Revance Therapeutics and related companies with MarketBeat.com’s FREE daily email newsletter.



Source link